Targeting neurotrophic signal transduction pathways in the treatment of mood disorders

Current Signal Transduction Therapy

Volumn 2, Issue 2, 2007, Pages 101-110

  Gould, Todd D ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant; Bipolar disorder; Depression; Glycogen synthase kinase 3; Lithium; Manic depressive illness; Treatment; Valproate

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DESIPRAMINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HALOPERIDOL; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LITHIUM; MIFEPRISTONE; MOOD STABILIZER; NEUROTROPHIC FACTOR; OLANZAPINE; PHENELZINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAMIPEXOLE; RILUZOLE; RISPERIDONE; ROLIPRAM; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

AUTOPSY; BIPOLAR DISORDER; BRAIN BLOOD FLOW; BRAIN FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC RISK; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MANIA; MOOD DISORDER; MORBIDITY; MORTALITY; NAUSEA; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROMODULATION; NEUROPROTECTION; NEUROPSYCHIATRY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT OUTCOME; VOMITING;

EID: 34249308861     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436207780619518     Document Type: Review

References (142)

1. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58: 175-89.
2. Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003; 64: 425-32.
3. Potash JB, DePaulo JR, Jr. Searching high and low: a review of the genetics of bipolar disorder. Bipolar Disord 2000; 2: 8-26.
4. Craddock N, Jones I. Genetics of bipolar disorder. J Med Genet 1999; 36: 585-94.
5. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552-62.
6. Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28: 335-41.
7. Manji HK, Gottesman, II, Gould TD. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci STKE 2003; 2003: pe49.
8. Petronis A. Epigenetics and bipolar disorder: new opportunities and challenges. Am J Med Genet 2003; 123C: 65-75.
9. Lenox RH, Gould TD, Manji HK. Endophcnotypes in bipolar disorder. Am J Med Genet 2002; 114: 391-406.
10. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
11. Gould TD, Gottesman II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav 2006; 5(2): 113-9.
12. Schou M. Lithium treatment at 52. J Affect Disord 2001; 67: 21-32.
13. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-88.
14. Bowden CL. Treatment options for bipolar depression. J Clin Psychiatry 2005; 66(Suppl 1): 3-6.
15. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994; 151: 169-76.
16. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.
17. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004; 9: 734-55.
18. Quiroz JA, Singh J, Gould TD, et al. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry 2004; 9: 756-76.
19. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001; 104: 569-80.
20. Gottesman, II, Shields J. A polygenic theory of schizophrenia. Proc Natl Acad Sci USA 1967; 58: 199-205.
21. Manji HK, Chen G. Post-receptor signaling pathways in die pathophysiology and treatment of mood disorders. Curr Psychiatry Rep 2000; 2: 479-89.
22. Crawley JN. What's wrong with my mouse? behavioral phenotyping of transgenic and knockout mice. New York: Wiley-Liss; 2000.
23. Tecott LH. The genes and brains of mice and men. Am J Psychiatry 2003; 160: 646-56.
24. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383: 707-10.
25. Minassian BA, Lee JR, Herbrick JA, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 1998; 20: 171-4.
26. Allen KM, Gleeson JG, Bagrodia S, et al. PAK3 mutation in nonsyndromic X-linked mental retardation. Nat Genet 1998; 20: 25-30.
27. De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev 2000; 33: 1-12.
28. Petronis A. Human morbid genetics revisited: relevance of epigenetics. Trends Genet 2001; 17: 142-6.
29. Lee CJ, Irizarry K. Alternative splicing in the nervous system: an emerging source of diversity and regulation. Biol Psychiatry 2003; 54: 771-6.
30. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813.
31. van der Laan JW, de Boer T, Bruinvels J. Di-n-propylacetale and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J Neurochem 1979; 32:1769-80.
32. Anlezark GM, Horton RW, Meldrum, BS, Sawaya MC, Stephenson JD. Proceedings: gamma-Aminobutyric acid metabolism and the anticonvulsant action of ethanolamine-o-sulphate and di-n-propylacetate. Br J Pharmacol 1976; 56: 383P-384P.
33. Sawaya MC, Horton RW, Meldrum BS. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia 1975; 16: 649-55.
34. Whittle SR, Turner AJ. Effects of the anticonvulsant sodium valproate on gamma-aminobutyrate and aldehyde metabolism in ox brain. J Neurochem 1978; 31: 1453-9.
35. Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000; 37: 103-10.
36. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 2001; 20: 6969-78.
37. Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-41.
38. Gould TD, Chen G, Manji HK, Mood stabilizer psychopharmacology. Clin Neurosci Res 2002; 2: 193-212.
39. Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002; 96: 45-66.
40. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996; 153: 151-62.
41. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160.
42. Gould TD, Manji HK. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 2002; 53: 687-697.
43. Manji HK, Chen G, Hsiao JK, et al. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996; 57: 34-46; discussion 47-8.
44. Plotsky PM, Owens MJ, Nemeroff CH. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998; 21: 293-307.
45. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42.
46. Nemeroff CB. New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Hum Psychopharmacol 2002; 17(Suppl 1): S13-6.
47. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003; 417: 38-50.
48. Mamounas LA, Blue ME, Siuciak JA, Altar CA. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 1995; 15: 7929-39.
49. Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 1999; 286: 2358-61.
50. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 2001; 11: 272-80.
51. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
52. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732-9.
53. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
54. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999; 46: 1181-91.
55. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-7.
56. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-61.
57. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001; 49: 753-62.
58. Monteggia LM, Barrot M, Powell CM, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827-32.
59. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
60. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
61. Henn FA, Vollmayr B. Neurogenesis and depression: etiology of epiphenomenon? Biol Psychiatry 2004; 56: 146-50.
62. Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry 2004; 56: 140-5.
63. Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry 2004; 56: 137-9.
64. Vollmayr B, Simonis C, Weber S, Gass P, Henn F. Reduced cell proliferation in the dentate gyrus is not correlated with the development of learned helplessness. Biol Psychiatry 2003; 54: 1035-40.
65. Yuan PX, Huang LD, Jiang YM, et al. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276: 31674-83.
66. Einat H, Yuan P, Gould TD, et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311-6.
67. Hao Y, Creson T, Zhang L, et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004; 24: 6590-9.
68. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bc1-2 in the CNS. J Neurochem 1999; 72: 879-82.
69. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-34.
70. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuro-protection against excitotoxicity. J Biol Chem 1999; 274: 6039-42.
71. Kim JS, Chang MY, Yu IT, et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J Neurochem 2004; 89: 324-36.
72. Son H, Yu IT, Hwang SJ, et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem 2003; 85: 872-81.
73. Chuang DM, Chen R, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disorders 2002; 4: 129-16.
74. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999; 46: 929-40.
75. (2+)-valproate in cultured cerebellar neurons. Funct Neurol 1995; 10: 121-30.
76. 2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995; 16: 187-98.
77. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48: 740-54.
78. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80: 589-97.
79. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-9.
80. Gould TD, Manji HK. The wnt signaling pathway in bipolar disorder. Neuroscientist 2002; 8: 497-511.
81. Gould TD, Manji HK, Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005; 30: 1223-37.
82. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 2004; 55: 781-4.
83. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 1-4.
84. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24: 6791-8.
85. Li X, Zhu W, Roh MS, et al. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsycho-pharmacology 2004; 29: 1426-31.
86. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099-104.
87. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079-86.
88. Tremolizzo L, Carboni G, Ruzicka WB, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci USA 2002; 99: 17095-100.
89. Yildirim E, Zhang Z, Uz T, et al. Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. Neurosci Lett 2003; 345: 141-3.
90. Jeong MR, Hashimoto R, Senatorov VV, et al. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett 2003; 542: 74-8.
91. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005; 280: 556-63.
92. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23: 9418-27.
93. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and beat shock protein induction. J Neurochem 2004; 89: 1358-67.
94. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-2.
95. Moore GJ, Bebchuk JM, Hasanat K, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2′s neurotrophic effects? Biol Psychiatry 2000; 48: 1-8.
96. Seibyl JP, Scanley BE, Krystal JH, Innis RB. Neuroimaging methodologies: utilizing radiotracers or nuclear magnetic resonance. In: Charney DS, Nester EJ, eds, Neurobiology of Mental Illness 2 ed. New York, Oxford University Press 2004; 190-209.
97. Lopez JF, Neale CR, Meader-Woodruff JH. Methods of postmortem investigation of the human brain. In: Charney DS, Nester EJ, eds, Neurobiology of Mental Illness 2 ed. New York, Oxford University Press 2004.
98. Drevets WC, Price JL, Simpson JR, Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386: 824-7.
99. Drevets WC, Gadde K, Krishnan R. Neuroimaging studies of depression. In: Charney DS, Nester EJ, Bunney BS, eds, Neurobiology of Mental Illness. New York, NY, Oxford University Press 1999; 394-418.
100. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002; 4: 129-116.
101. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-7.
102. Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM. Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry 2000; 48: 505-17.
103. Altshuler LL, Curran JG, Hauser P, et al. T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. Am J Psychiatry 1995; 152: 1139-44.
104. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr Scand 1997; 96: 157-68.
105. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813-29.
106. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48: 766-77.
107. Charney DS, Manji HK. Life stress, genes, and depression: multiple path-ways lead to increased risk and new opportunities for intervention. Sci STKE 2004; 2004: re5.
108. Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry 1998; 155: 457-69.
109. Kandel ER. Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited. Am J Psychiatry 1999; 156: 505-24.
110. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44: 324-35.
111. Fujimaki K, Morinobu S, Duman RS. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 2000; 22: 42-51.
112. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984; 17: 188-90.
113. Bobon D, Breulet M, Gerard-Vandenbove MA, et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 1988; 238: 2-6.
114. Hebenstreit GF, Fellerter K, Fichte K, et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989; 22:156-60.
115. Zhu J, Mix E, Winblad B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev 2001; 7: 387-98.
116. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35: 5-49.
117. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
118. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 2041-6.
119. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 579-93.
120. Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36:35-83.
121. Bannerman DM, Good MA, Butcher SP, Ramsay M, Morris RG. Distinct components of spatial learning revealed by prior training and NMDA receptor blockade. Nature 1995; 378: 182-6.
122. Collingridge GL. Long-term potentiation. A question of reliability. Nature 1994; 371: 652-3.
123. Watkins J, Collingridge G. Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. Trends Pharmacol Sci 1994; 15: 333-42.
124. Collingridge GL, Bliss TV. Memories of NMDA receptors and LTP. Trends Neurosci 1995; 18: 54-6.
125. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
126. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
127. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250: 473-6.
128. Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology 2003; 167: 219-220.
129. Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry 2004; 161: 2132.
130. Singh J, Zarate CA, Jr., Krystal AD. Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology (Berl) 2004; 173: 227-8.
131. Zarate CA, Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171-4.
132. Zarate CA, Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430-2.
133. Berman RM, Cappiello A. Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4.
134. Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004; 65: 10-21.
135. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-6.
136. Zarate CA, Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60.
137. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 2001; 49: 1023-39.
138. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci 1999; 22: 105-22.
139. McEwen BS. Effects of adverse experiences for brain structure and function. Biol Psychiatry 2000; 48: 721-31.
140. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000; 21: 55-89.
141. Hasler G, Drevets WC, Manji BY, Charney DS. Discovering endopheno-types for major depression. Neuropsychopharmacology 2004; 29: 1765-81.
142. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 2006; 60(2): 92-105.